ICMR-INDIAB-17 — India Diabetes Burden

Source: The Lancet Diabetes & Endocrinology (2023).

Key finding: 101.3M with diabetes, 254M with obesity.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
GLP-1 Receptor Agonists and the Cardiovascular and Kidney Outcomes: A Meta-Analysis of Randomized Trials
Semaglutide for the Treatment of Obesity: A Comprehensive Review
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

Take the Free Eligibility Assessment → · Compare All 18+ Brands